# Dewpoint Therapeutics' DPTX8743 to Enter Phase 1/2a Trial Funded by Cancer Research UK

> Cancer Research UK will fund and run a first-in-human Phase 1/2a trial of Dewpoint Therapeutics' MYC condensate modulator DPTX8743.

- Published: 2026-11-17T08:40:00+00:00
- Section: Partnerships
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-17/dewpoint-dptx8743-cancer-research-uk-trial
- Source: [TradingView](https://www.tradingview.com/news/tradingview:f46c0b0be9163:0-dewpoint-therapeutics-advances-dptx8743-to-a-funded-phase-1-2a-trial/)

## Key takeaways

- Cancer Research UK's Centre for Drug Development will fund, sponsor and execute CTA-enabling studies and a Phase 1/2a trial of DPTX8743.
- Dewpoint Therapeutics retains all rights to DPTX8743 and may license the results and intellectual property.
- Cancer Research UK is eligible for downstream milestones and royalties, with no amounts or specific milestones disclosed.
- Dewpoint selected its first MYC condensate modulator development candidate in February 2026.

Cancer Research UK will fund, sponsor and execute a first-in-human Phase 1/2a trial of [Dewpoint Therapeutics](https://akta.pro/company-profiles/00004aa/dewpoint-therapeutics)' DPTX8743, including CTA-enabling studies, the company said in a release covered by [TradingView](https://www.tradingview.com/news/tradingview:f46c0b0be9163:0-dewpoint-therapeutics-advances-dptx8743-to-a-funded-phase-1-2a-trial/). No agreement value or cost to Dewpoint was disclosed.

## How the DPTX8743 Trial Will Run

DPTX8743 is described as a potential first-in-class small molecule modulator of MYC condensates, aimed at a cancer driver the release calls historically undruggable. Cancer Research UK's Centre for Drug Development has agreed to fund, sponsor and execute the CTA-enabling studies and the Phase 1/2a trial. The collaboration is designed to evaluate safety and establish clinical proof of concept across MYC-driven cancers with high unmet need.

Dewpoint keeps all rights to DPTX8743 and may license the results and intellectual property. [Cancer Research UK](https://akta.pro/company-profiles/0005huh/cancer-research-uk) is eligible for downstream milestones and royalties; no amounts or specific milestones were disclosed. The release cites preclinical findings and no human results, and gives no timing or trial start date.

Cancer Research UK has backed a private member's bill requiring annual government reporting on cancer prevention, diagnosis and treatment, BBC reported on November 13, 2026, alongside 64 charities.

## Dewpoint's Earlier Pipeline Steps

Dewpoint selected its first-in-class MYC condensate modulator development candidate in February 2026, according to akta.pro [company records](https://akta.pro/company-data), extending its oncology pipeline beyond Wnt-driven cancers. The same records show Dewpoint dosed the first patient in a Phase 1a/2a trial of DPTX3186 for advanced Wnt-pathway activated solid tumors, focused on gastric cancer, in February 2026. The records list a Series D financing of $77.2 million in September 2025 and total funding of $367.6 million.

## Trial Partnerships Elsewhere

NAMSA and Advanced Medical Solutions announced a preferred partnership on November 9, 2026, consolidating NAMSA's regulatory, testing and clinical services under one partner, [PR Newswire](https://www.prnewswire.com/news-releases/namsa-and-advanced-medical-solutions-announce-preferred-partnership-302932400.html) reported. Istios Health partnered with Arkansas Renal Group to expand its cardiovascular-kidney-metabolic clinical research network into Arkansas, [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-12-istios-health-expands-clinical-research-network-into-arkansas-through-arkansas-renal-group-partnership) reported on November 12, 2026. K-MedHub and the Korea Brain Research Institute signed a cooperation agreement on May 5, [Naver](https://n.news.naver.com/mnews/article/002/0002464630) reported on November 6, 2026, covering shared non-human primate facilities and joint national R&D planning.

## Companies in this story

- [Dewpoint Therapeutics company profile](https://akta.pro/company-profiles/00004aa/dewpoint-therapeutics) · website: https://dewpointx.com
- [Cancer Research UK company profile](https://akta.pro/company-profiles/0005huh/cancer-research-uk) · website: http://www.cancerresearchuk.org

---
News for Agent · https://newsforagent.com/llms.txt
